New Mobile Device Uses Breath to Monitor Opioid Adherence

nGageIT’s NanoSmart determines medication adherence with a biosensor that tests the patient’s breath.

Mobile Device Breathalyzer / Image: nGageIT
Mobile Device Breathalyzer / Image: nGageIT

Curbing drug abuse and improving compliance is top of mind for many drug companies in the midst of the opioid epidemic. A recent MobiHealthNews article reported on a new device that uses a patient’s breath in order to determine medication adherence. The product, NanoSmart, was developed by Toronto-based digital health company nGageIT.

The platform’s special sauce is a biosensor detection technology that fits into a smartphone, dubbed the “Noz.” When a patient breathes into the Noz, an interior dongle detects ingestible nanoparticles of drugs and sends the information to a mobile phone. It’s also capable of sending adherence data to a doctor or the patient’s EHR via the cloud.

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026